29 Mar 2021 09:00
REDX PHARMA PLC
("Redx" or "the Company")
Redx Pharma to present at the American Association for Cancer Research Annual Meeting
Alderley Park, 29 March 2021 Redx Pharma (AIM:REDX), the drug discovery and development Company focused on oncology and fibrosis, today announces that it will present a poster entitled 'Mechanism of action of RXC004, a Wnt pathway inhibitor, in genetically-defined models of cancer' at the American Association for Cancer Research (AACR) Annual Meeting, being held virtually on 10 April 2021.
The poster relates to the Company's lead oncology candidate, RXC004, a selective, orally bioavailable porcupine inhibitor targeting the Wnt signalling pathway. The poster will present preclinical data on the potential for the direct tumour-targeting effects of RXC004 in genetically defined models of cancer.
Poster presentation:
Title: Mechanism of action of RXC004, a Wnt pathway inhibitor, in genetically-defined models of cancer
Abstract: #998
Session name and category: Session PO.ET02.02 - Cellular Responses to Anticancer Drugs
The abstract is available via the AACR annual meeting website, here: https://www.abstractsonline.com/pp8/#!/9325/presentation/2070
Copies of the poster will be available on the scientific publication page of Redx's website following the conference at https://www.redxpharma.com/scientific-publications/.
For further information, please contact: | |
Redx Pharma Plc | T: +44 1625 469 918 |
Iain Ross, Chairman Lisa Anson, Chief Executive James Mead, Chief Financial Officer | |
SPARK Advisory Partners (Nominated Adviser) | T: +44 203 368 3550 |
Matt Davis/Adam Dawes | |
WG Partners LLP (Joint Broker) | T: +44 20 3705 9330 |
Claes Spång/Chris Lee/David Wilson | |
Panmure Gordon (UK) Limited (Joint Broker) | T: +44 20 7886 2500 |
Rupert Dearden/Freddy Crossley/Emma Earl | |
FTI Consulting | T: +44 20 3727 1000 |
Simon Conway/Ciara Martin | |
|
About RXC004
RXC004 is a potent, selective, oral small molecule inhibitor of the enzyme, Porcupine, a key activator of Wnt ligands in the Wnt signalling pathway. Aberrant Wnt signalling contributes directly to tumour growth and plays an important role in immune resistance to treatment with immuno-oncology agents such as anti-PD-1 checkpoint inhibitors.
By selecting patients with tumours that have high Wnt ligand dependency, such as tumours with mutations in the RNF43 gene and fusions in the RSPO gene family, RXC004 has an opportunity to directly target tumour in addition to having an immune-enhancing effect.
RXC004 is currently in a phase 1 study, with top line data expected in H1 2021. Clinical proof-of-concept studies in genetically-selected patients with metastatic colorectal cancer (monotherapy and immuno-oncology combination), genetically selected pancreatic cancer and all comers biliary cancer are expected to initiate following completion of phase 1.
About Redx Pharma Plc
Redx Pharma (AIM:REDX) is focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic disease, aiming to progress them to clinical proof of concept. Redx's lead oncology asset, RXC004, is currently in a phase 1 study in patients with advanced malignancies with top line data expected in H1 2021 and the Company's selective ROCK2 inhibitor, RXC007, is expected to enter a phase 1 clinical study in H1 2021.
The Company's core capability of converting medicinal chemistry insights into differentiated and commercially attractive small molecule drug candidates against clinically validated targets has been recognized by others. Over the last three years the company has completed four major preclinical stage deals with AstraZeneca, Jazz Pharmaceuticals and Loxo Oncology (now Eli Lilly).